• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Advertise
  • Subscribe

MassDevice

The Medical Device Business Journal — Medical Device News & Articles | MassDevice

  • Latest News
  • Technologies
    • Artificial Intelligence (AI)
    • Cardiovascular
    • Orthopedics
    • Neurological
    • Diabetes
    • Surgical Robotics
  • Business & Finance
    • Wall Street Beat
    • Earnings Reports
    • Funding Roundup
    • Mergers & Acquisitions
    • Initial Public Offering (IPO)
    • Legal News
    • Personnel Moves
    • Medtech 100 Stock Index
  • Regulatory & Compliance
    • Food & Drug Administration (FDA)
    • Recalls
    • 510(k)
    • Pre-Market Approval (PMA)
    • MDSAP
    • Clinical Trials
  • Special Content
    • Special Reports
    • In-Depth Coverage
    • DeviceTalks
  • Podcasts
    • MassDevice Fast Five
    • DeviceTalks Weekly
    • OEM Talks
      • AbbottTalks
      • Boston ScientificTalks
      • DeviceTalks AI
      • IntuitiveTalks
      • MedtechWOMEN Talks
      • MedtronicTalks
      • Neuro Innovation Talks
      • Ortho Innovation Talks
      • Structural Heart Talks
      • StrykerTalks
  • Resources
    • About MassDevice
    • DeviceTalks
    • Newsletter Signup
    • Leadership in Medtech
    • Manufacturers & Suppliers Search
    • MedTech100 Index
    • Videos
    • Webinars
    • Whitepapers
    • Voices
Home » Outset Medical faces shareholder lawsuit after shipment hold

Outset Medical faces shareholder lawsuit after shipment hold

July 18, 2022 By Chris Newmarker

Outset Medical logoOutset Medical (Nasdaq: OM) is facing a shareholder lawsuit in federal court, a month after it announced a shipping hold on its Tablo hemodialysis system for home use.

The company said on June 13 that it was holding off shipments amid a pending FDA review and clearance of a 510(k) submitted for changes made since the Tablo system’s original March 2020 clearance. The shipment hold news caused OM shares to lose more than a third of their value the next day. The company’s stock is down by nearly two-thirds over the past year, presently trading at around $16 per share.

Lawyers at Saxena White P.A. filed a lawsuit on July 8 in U.S. District Court in Northern California on behalf of the Plaintiff Plymouth County Retirement Association in Massachusetts and other Outset Medical shareholders. The lawsuit claims that the company and its top executives made false and misleading positive statements leading up to the shipment hold announcement.

Other law firms have issued news releases seeking shareholders to join potential class action lawsuits.

In a statement that a spokesperson shared with MassDevice, Outset Medical declined to comment about active litigation, other than to say that it intends to vigorously defend itself.

David Kaplan and Wolfram Worms of Saxena White point to Outset Medical’s annual report that it filed in February. The annual report disclosed that the company had to submit a “catch-up” 510(k) application to the FDA to cover design changes — but it did not mention that it could lead to a shipment hold, according to the complaint.

During the company’s Q1 earnings announcement in May, Outset Medical executives expressed enough optimism in its outlook that they upped the lower end of its 2022 revenue guidance range to $144–150 million from a previous $142–150.

The complaint alleges that between Outset Medical’s IPO in September 2020 and the June 13 announcement, misstatements and omissions from the company and its management “had the cause and effect of creating in the market an unrealistically positive assessment of the company and its business, thus causing the company’s common stock to be overvalued and artificially inflated or maintained at all relevant times.”

Filed Under: Business/Financial News, Dialysis, Digital Health, Featured, Legal News, News Well, Wall Street Beat Tagged With: Outset Medical

More recent news

  • Johnson & Johnson MedTech launches new Volt plating systems for radius, humerus
  • PharmaSens, SiBionics collab on all-in-one insulin patch pump
  • Beta Bionics to pair iLet automated insulin delivery system with Abbott’s dual glucose-ketone sensor
  • Anaconda Biomed wins CE mark for funnel catheter
  • FDA approves Neuspera neuromod for urinary incontinence

About Chris Newmarker

Chris Newmarker is the executive editor of WTWH Media life science's news websites and publications including MassDevice, Medical Design & Outsourcing and more. A professional journalist of 18 years, he is a veteran of UBM (now Informa) and The Associated Press whose career has taken him from Ohio to Virginia, New Jersey and, most recently, Minnesota. He’s covered a wide variety of subjects, but his focus over the past decade has been business and technology. He holds bachelor’s degrees in journalism and political science from Ohio State University. Connect with him on LinkedIn or email at [email protected].

Primary Sidebar

“md
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest med device regulatory, business and technology news.

DeviceTalks Weekly

See More >

MEDTECH 100 Stock INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
MDO ad

Footer

MASSDEVICE MEDICAL NETWORK

DeviceTalks
Drug Delivery Business News
Medical Design & Outsourcing
Medical Tubing + Extrusion
Drug Discovery & Development
Pharmaceutical Processing World
MedTech 100 Index
R&D World
Medical Design Sourcing

DeviceTalks Webinars, Podcasts, & Discussions

Attend our Monthly Webinars
Listen to our Weekly Podcasts
Join our DeviceTalks Tuesdays Discussion

MASSDEVICE

Subscribe to MassDevice E-Newsletter
Advertise with us
About
Contact us

Copyright © 2025 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Privacy Policy